These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14051510)

  • 1. EVALUATION OF ANTILEUKEMIC AGENTS IN THE TREATMENT OF DRUG RESISTANT VARIANTS OF LEUKEMIA L1210.
    VENDITTI JM; GOLDIN A
    Cancer Res; 1963 Jul; 23():SUPPL1011-84. PubMed ID: 14051510
    [No Abstract]   [Full Text] [Related]  

  • 2. EVALUATION OF ANTILEUKEMIC AGENTS EMPLOYING ADVANCED LEUKEMIA L1210 IN MICE. 8.
    VENDITTI JM; KLINE I; GOLDIN A
    Cancer Res; 1964 Jul; 24():827-79. PubMed ID: 14204394
    [No Abstract]   [Full Text] [Related]  

  • 3. EVALUATION OF ANTILEUKEMIC AGENTS EMPLOYING ADVANCED LEUKEMIA L1210 IN MICE. VII.
    VENDIITI JM; SHELDON DR; GOLDIN A
    Cancer Res; 1964 Jan; 24():145-96. PubMed ID: 14106543
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. II.
    GOLDIN A; VENDITTI JM; KLINE I; MANTEL N
    Cancer Res; 1960 Jun; 20(5)Pt 2():382-469. PubMed ID: 13850662
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196).
    Tyrer DD; Kline I; Gang M; Goldin A; Venditti JM
    Cancer Chemother Rep; 1969 Sep; 53(4):229-41. PubMed ID: 5384463
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
    Kline I; Woodman RJ; Gang M; Venditti JM
    Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
    [No Abstract]   [Full Text] [Related]  

  • 7. ACTIVITY OF SELECTED COMPOUNDS IN SUBLINE OF LEUKEMIA L1210 RESISTANT TO CYTOSINE ARABINOSIDE (NSC-63878).
    WODINSKY I; KENSLER CJ
    Cancer Chemother Rep; 1964 Dec; 43():1-3. PubMed ID: 14250647
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII.
    Venditti JM; Sheldon DR; Goldin A
    Cancer Res; 1964 Jan; 24(1 Pt 1):145-210. PubMed ID: 5878215
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the effectiveness of 4',4"-di-2-imidazolin-2-ylterephthalanilides against mouse leukemia L1210 and resistant variants.
    VENDITTI JM; GOLDIN A; KLINE I
    Cancer Chemother Rep; 1962 Jun; 19():5-11. PubMed ID: 13925303
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of antileukemic agents employing advanced leukemia L-1210 in mice. VI.
    GOLDIN A; VENDITTI JM; KLINE I
    Cancer Res; 1962 Sep; 2():749-835. PubMed ID: 13948731
    [No Abstract]   [Full Text] [Related]  

  • 12. CHEMOTHERAPY OF ADVANCED MOUSE LEUKEMIA L1210: COMPARISON OF METHOTREXATE ALONE AND IN SEQUENTIAL THERAPY.
    VENDITTI JM; GOLDIN A
    Cancer Res; 1964 Sep; 24():1457-60. PubMed ID: 14221802
    [No Abstract]   [Full Text] [Related]  

  • 13. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
    SKIPPER HE; SCHABEL FM; WILCOX WS
    Cancer Chemother Rep; 1964 Feb; 35():1-111. PubMed ID: 14117037
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 15. Antileukemic effects of 5-(2-dimethylaminoethoxy)-7-oxo-7H-benzo(c) fluorene, substance VUFB 13 468, on L1210 and La leukemia.
    Pujman V; Cernochová S
    Neoplasma; 1981; 28(6):715-20. PubMed ID: 7339500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.
    Kline I; Venditti JM; Mead JA; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):848-52. PubMed ID: 5934795
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined therapy of L1210 leukemia with Damvar and cytostatics.
    Pujman V; Cernochová S
    Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HYDROXYUREA. A NEW TYPE OF POTENTIAL ANTITUMOR AGENT.
    STEARNS B; LOSEE KA; BERNSTEIN J
    J Med Chem; 1963 Mar; 6():201. PubMed ID: 14188794
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells.
    Iwasaki H; Liu YP; Nojyo Y; Ueda T; Nakamura T
    Anticancer Res; 1995; 15(1):133-9. PubMed ID: 7733623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.